Delivery Order SPE2DR25D1109-SPE2DR26FFJ2K
- Not listed
- The Defense Logistics Agency awarded a $3,900.48 delivery order to AmerisourceBergen Drug Corp for Promethegan 25 mg suppositories (12 count) on September 24, 2025, with completion targeted for September 25, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Promethegan 25 mg suppositories (12-count units) with a ceiling value of $14,649.54. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a non-competitive award issued under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $1,782.98 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Promethegan 25 mg suppositories (12-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of August 15, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this delivery order is issued under...
- The Defense Logistics Agency awarded a $7,329.92 delivery order to AmerisourceBergen Drug Corp for Promethegan 25 mg suppositories on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-set-aside competitive award to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this order as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Promethegan 25 mg suppositories (12-count packages) valued at $1,383.72 with a completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $1,794.40 firm fixed price delivery order to provide PROMETHEGAN 25 MG SUPPOSITORY 12S pharmaceutical products. This order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,510.02, is for the supply of 4567844138 PROMETHEGAN 25 MG SUPPOSITORY 12S. This order is not designated as a set-aside. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,154.94, is a Firm Fixed Price Delivery Order for the pharmaceutical product "PROMETHEGAN 12.5 MG SUPPOS 12S". The contract has an ultimate completion date of January 21, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,289.09, is for the delivery of a medical product called PROMETHEGAN 50 MG SUPPOSITORY. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC,...
- The Defense Logistics Agency awarded a delivery order valued at $1,600.29 to AmerisourceBergen Drug Corp for the supply of Prometrium 200 mg capsules (30-count) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical procurement supporting federal medical supply needs. The place of performance is AmerisourceBergen's corporate office in...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFJ2KDelivery Order
The Defense Logistics Agency awarded a $1,400.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Promethegan 25 mg suppositories (12-count package) on December 17, 2025, with completion expected by December 18, 2025. This non-competitive, non-set-aside delivery order represents a pharmaceutical supply transaction issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle extending through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp maintains extensive delivery order activity through its DLA master contract, supplying a comprehensive range of medications and medical supplies to support military healthcare systems and the Defense Health Agency. This specific delivery order for Promethegan, an antihistamine suppository medication, exemplifies the company's role in fulfilling routine pharmaceutical procurement requirements for federal medical supply chains. The firm fixed-price structure and narrow completion window indicate routine inventory replenishment activity within the broader framework of DLA's pharmaceutical prime vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 12/16/25 |